Busca avançada
Ano de início
Entree


Texto completo
Autor(es):
Mostrar menos -
Santos, Barbara Chaves ; Alves, Bruna Cherubini ; Fonseca, Ana Luisa Ferreira ; Ferreira, Samanta Catherine ; Mizubuti, Yani Glaucia Gomide ; Saueressig, Camila ; Boulhosa, Ramona Souza da Silva Baqueiro ; Santos, Livia Alves Amaral ; Cunha, Carla de Magalhaes ; Lyra, Andre Castro ; Oliveira, Lucivalda Pereira Magalhaes ; de Jesus, Rosangela Passos ; Romeiro, Fernando Gomes ; Dall'Alba, Valesca ; Luft, Vivian Cristine ; Correia, Maria Isabel Toulson Davisson ; Ferreira, Livia Garcia ; Anastacio, Lucilene Rezende
Número total de Autores: 18
Tipo de documento: Artigo Científico
Fonte: European Journal of Clinical Nutrition; v. N/A, p. 6-pg., 2025-01-14.
Resumo

Objectives: This study aimed to define handgrip strength (HGS) cutoff points to predict 1-year mortality in adult patients with liver cirrhosis. Methods: This is an analysis of cohort databases from four reference centers in Brazil. Inpatients or outpatients with cirrhosis and aged >= 18 years were included. The best cutoff values of HGS (highest value from three attempts with the non-dominant hand) for predicting 1-year mortality, stratified by sex and age, were established based on the sensitivity and specificity analyses. Adjusted Cox regression models were used to test the predictive value of low HGS. Results: The study included 724 patients with cirrhosis, with a median age of 57.0 years (IQR: 50.0-63.0), 66.4% (n = 481) male. Most patients had alcoholic cirrhosis (n = 281; 38.8%), 400 (55.3%) were classified as Child-Pugh B or C, and 134 (18.5%) patients died after 1-year. The HGS cutoffs were <= 33 kgf and <= 12 kgf for men and women aged <60 years, respectively, and <= 22 kgf and <= 10 kgf for older men and women, respectively (sensitivity: 70.9%; specificity: 61.2%). Low HGS was associated with a 2.5-fold increase in the risk of 1-year mortality. Conclusion: These cutoff points could be used to identify patients with a higher mortality risk. (AU)

Processo FAPESP: 16/07117-9 - Risedronato no tratamento de osteoporose em portadores de cirrose com varizes esofágicas: avaliação sobre segurança e eficácia na recuperação da massa óssea
Beneficiário:Fernando Gomes Romeiro
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 14/22572-9 - Resposta ao tratamento da osteoporose e da osteopenia em portadores de cirrose hepática
Beneficiário:Lívia Alves Amaral Santos
Modalidade de apoio: Bolsas no Brasil - Doutorado